Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Currently, limited information is available to clinicians regarding the long-term efficacy of omalizumab treatment for allergic asthma. In this report, we aimed to (i) systematically review the evidence regarding the long-term efficacy of omalizumab in patients with persistent uncontrolled allergic asthma and to (ii) discuss the cost-effectiveness evidence published for omalizumab in this patient population. A comprehensive search for randomized controlled trials (RCTs; ≥52 weeks) was performed and six studies met our final inclusion criteria (n = 2,749). Omalizumab was associated with significant improvements in quality of life and the Global Evaluation of Treatment Effectiveness. Omalizumab also allowed patients to completely withdraw from inhaled corticosteroid therapy and did not increase the overall incidence of adverse events. However, there was insufficient evidence that omalizumab reduced the incidence of exacerbations and the cost-effectiveness of omalizumab varied across studies. Our data indicated that omalizumab use for at least 52 weeks in patients with persistent uncontrolled allergic asthma was accompanied by an acceptable safety profile, but it lacked effect on the asthma exacerbations. Use of omalizumab was associated with a higher cost than conventional therapy, but these increases may be cost-effective if the medication is used in patients with severe allergic asthma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“There is evidence for acceptable safety for use up to 52 weeks.1821”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [1821]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00136 · Cited by 10,349
Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma
Program, P., & theDiagnosis, T. E. P. O. (1997) · Cited by 4,926
Busse, W., Corren, J., Lanier, B. Q., McAlary, M., Fowler-Taylor, A., Cioppa, G. D., van As, A., & Gupta, N. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.117880 · Cited by 1,307
Humbert, M., Beasley, R., Ayres, J., Slavin, R., Hébert, J., Bousquet, J., Beeh, K. ‐., Ramos, S., Canonica, G. W., Hedgecock, S., et al. (2005) · Allergy · doi:10.1111/j.1398-9995.2004.00772.x · Cited by 1,123
Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children
Busse, W. W., Morgan, W. J., Gergen, P. J., Mitchell, H. E., Gern, J. E., Liu, A. H., Gruchalla, R. S., Kattan, M., Teach, S. J., Pongracic, J. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009705 · Cited by 884
Solèr, M., Matz, J., Townley, R., Buhl, R., O'Brien, J., Fox, H., Thirlwell, J., Gupta, N., & Della Cioppa, G. (2001) · European Respiratory Journal · doi:10.1183/09031936.01.00092101 · Cited by 827
Omalizumab for asthma in adults and children
Normansell, R., Walker, S., Milan, S. J., Walters, E. H., & Nair, P. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003559.pub4 · Cited by 651
Research works printed but not linked: 3
- National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. <http://www.ncbi.nlm.nih.gov/books/NBK7232/> (2007) Date of access: 20/07/2014.
- Bardelas, J., Figliomeni, M., Kianifard, F. & Meng, X. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma. J Asthma 49, 44–52 (2012). · DOI
- Lanier, B. Q. et al. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 91,154–159 (2003). · DOI · Paper page
Cited by
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials
Gevaert, P., Omachi, T. A., Corren, J., Mullol, J., Han, J., Lee, S. E., Kaufman, D., Ligueros-Saylan, M., Howard, M., Zhu, R., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.032 · Cited by 739
International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
Wise, S. K., Lin, S. Y., Toskala, E., Orlandi, R. R., Akdis, C. A., Alt, J. A., Azar, A., Baroody, F. M., Bachert, C., Canonica, G. W., et al. (2018) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22073 · Cited by 557
Asthma phenotypes and IgE responses
Froidure, A., Mouthuy, J., Durham, S. R., Chanez, P., Sibille, Y., & Pilette, C. (2016) · European Respiratory Journal · doi:10.1183/13993003.01824-2014 · Cited by 267
Li, J., Fan, L., Li, M.-H., Cao, W.-J., & Xu, J. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.11.019 · Cited by 130
Asthma biomarkers in the age of biologics
Kim, H. L., Ellis, A. K., Fischer, D., Noseworthy, M., Olivenstein, R., Chapman, K. R., & Lee, J. (2017) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-017-0219-4 · Cited by 125
“Initial trials demonstrating the safety and effectiveness of omalizumab in the management of moderate to severe allergic asthma [18–23] are supported by long-term (≥ 52 weeks) and real-world studies [188–191] and more than 400,000 patient-years of experience [192].”
BackgroundSelected comorbidities of atopic dermatitis: Atopy, neuropsychiatric, and musculoskeletal disorders
Silverberg, J. I. (2017) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2017.03.008 · Cited by 105
Past, present, and future of anti‐IgE biologics
Guntern, P., & Eggel, A. (2020) · Allergy · doi:10.1111/all.14308 · Cited by 94
Mansur, A. H., Srivastava, S., Mitchell, V., Sullivan, J., & Kasujee, I. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.01.008 · Cited by 79
Real-life Efficacy of Omalizumab After 9 Years of Follow-up
Menzella, F., Galeone, C., Formisano, D., Castagnetti, C., Ruggiero, P., Simonazzi, A., & Zucchi, L. (2017) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2017.9.4.368 · Cited by 75
“Another similar study by Lai et al.10 reported that while omalizumab is associated with higher costs than conventional therapies, it nonetheless appears to be cost-effective in patients with severe allergic asthma.”
BackgroundInfluentialControlling Mast Cell Activation and Homeostasis: Work Influenced by Bill Paul That Continues Today
Caslin, H. L., Kiwanuka, K. N., Haque, T. T., Taruselli, M. T., MacKnight, H. P., Paranjape, A. R., & Ryan, J. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00868 · Cited by 82
“More recently, a humanized anti-IgE antibody, omalizumab, has been developed to prevent binding of circulating IgE to FcεRI and the downstream effects of cross-linking (218, 219).”
BackgroundRItA: The Italian severe/uncontrolled asthma registry
Maio, S., Baldacci, S., Bresciani, M., Simoni, M., Latorre, M., Murgia, N., Spinozzi, F., Braschi, M., Antonicelli, L., Brunetto, B., et al. (2017) · Allergy · doi:10.1111/all.13342 · Cited by 66
“Indeed, a recent meta-analysis showed that anti-IgE-treated patients more likely underwent the withdrawal of corticosteroid therapy.(21) Italian patients showed high level of IgE, atopic status, and an eosinophilic inflammation pattern both at systemic and at airways level, confirming the importance of using biologica…”
BackgroundLambkin‐Williams, R., Noulin, N., Mann, A., Catchpole, A. P., & Gilbert, A. S. (2018) · Respiratory Research · doi:10.1186/s12931-018-0784-1 · Cited by 58
Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety
Giménez‐Arnau, A. M. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1285903 · Cited by 59
Maggi, L., Rossettini, B., Montaini, G., Matucci, A., Vultaggio, A., Mazzoni, A., Palterer, B., Parronchi, P., Maggi, E., Liotta, F., et al. (2018) · European Journal of Immunology · doi:10.1002/eji.201847668 · Cited by 57
Porsbjerg, C. M., Ulrik, C. S., Skjold, T., Backer, V., Lærum, B. N., Lehman, S., Janson, C., Sandström, T., Bjermer, L. H., Dahlén, B., et al. (2018) · European Clinical Respiratory Journal · doi:10.1080/20018525.2018.1440868 · Cited by 65
“The ERS/ATS guidelines on severe asthma published in 2014 define severe asthma as ‘asthma which requires treatment with high dose inhaled corticosteroids (ICS) plus a second controller or systemic CS, which remains “uncontrolled” despite this therapy, or to prevent it from becoming “uncontrolled”’ [1].”
BackgroundInfluentialInterleukin-31 expression and relation to disease severity in human asthma
Lai, T., Wu, D., Li, W., Chen, M., Yi, Z.-N., Huang, D. A., Jing, Z., Lü, Y., Lv, Q., Li, D., et al. (2016) · Scientific Reports · doi:10.1038/srep22835 · Cited by 52
Self-citationManaging problematic severe asthma: beyond the guidelines
Pike, K. C., Levy, M. L., Moreiras, J., & Fleming, L. (2017) · Archives of Disease in Childhood · doi:10.1136/archdischild-2016-311368 · Cited by 63
Roth‐Walter, F., Adcock, I. M., Benito‐Villalvilla, C., Bianchini, R., Bjermer, L. H., Caramori, G., Cari, L., Chung, K. F., Diamant, Z., Eguíluz‐Gracia, I., et al. (2018) · Allergy · doi:10.1111/all.13642 · Cited by 50
Chronic respiratory diseases: An introduction and need for novel drug delivery approaches
Shukla, S. D., Vanka, K. S., Chavelier, A., Shastri, M. D., Tambuwala, M. M., Bakshi, H. A., Pabreja, K., Mahmood, M. Q., & O’Toole, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820658-4.00001-7 · Cited by 80
Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review
Mansilla‐Polo, M., & Morgado‐Carrasco, D. (2024) · Dermatology and Therapy · doi:10.1007/s13555-024-01203-2 · Cited by 48
Anti-hIgE gene therapy of peanut-induced anaphylaxis in a humanized murine model of peanut allergy
Pagovich, O. E., Wang, B., Chiuchiolo, M. J., Kaminsky, S. M., Sondhi, D., Jose, C. L., Price, C. C., Brooks, S. F., Mezey, J. G., & Crystal, R. G. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.03.053 · Cited by 43
Personalised medicine in asthma: from curative to preventive medicine
Guilleminault, L., Ouksel, H., Belleguic, C., Guen, Y. L., Germaud, P., Desfleurs, E., Leroyer, C., & Magnan, A. (2017) · European Respiratory Review · doi:10.1183/16000617.0010-2016 · Cited by 43
Two decades with omalizumab: what we still have to learn
Incorvaia, C., Mauro, M., Makrì, E., Leo, G., & Ridolo, E. (2018) · Biologics · doi:10.2147/btt.s180846 · Cited by 39
“demonstrated, along with significant improvements in quality of life (QoL) as well as good safety and tolerability.(13)”
Wang, Y., Chen, Y., Xiang, C., Jiang, G.-W., Xu, Y., Yin, L.-M., Zhou, D., Liu, Y., & Yang, Y. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112635 · Cited by 40
Tat, T. S., & Çilli, A. (2016) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2016.09.006 · Cited by 38
Omalizumab for asthma and allergic bronchopulmonary aspergillosis in adults with cystic fibrosis
Koutsokera, A., Corriveau, S., Sykes, J. R., Coriati, A., Cortes, D., Vadas, P., Chaparro, C., McIntyre, K., Tullis, E. D., & Stephenson, A. L. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.07.011 · Cited by 39
Wang, N., Li, J., Huang, X., Chen, W., & Chen, Y. (2016) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2016/6134593 · Cited by 43
“In addition, several randomized clinical trials have been conducted, in order to assess the effectiveness and safety of combination therapies in human populations suffering from asthma, as regards the quality of life and the occurrence of asthma-associated comorbidities [12, 13].”
BackgroundInfluentialMonoclonal antibodies: the new magic bullets for allergy: IUPHAR Review 17
Landolina, N., & Levi‐Schaffer, F. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13396 · Cited by 38
Biologic agents for severe asthma patients: clinical perspectives and implications
Caruso, M., Morjaria, J. B., Emma, R., Amaradio, M. D., & Polosa, R. (2017) · Internal and Emergency Medicine · doi:10.1007/s11739-017-1773-y · Cited by 33
“Despite its efficacy [17–22, 27, 29, 31, 42, 43, 47], good safety profile [27, 29, 31, 49] and cost effectiveness as add-on therapy in patients with severe atopic asthma [28, 33, 96, 97], questions about its management in the clinical setting still remain unanswered.”
BackgroundAdherence to omalizumab: A multicenter "real-world" study
Campisi, R., Crimi, C., Intravaia, R., Strano, S., Noto, A., Barbaro, M. P. F., Valenti, G., Viviano, V., Pelaia, C., Ricciardi, L., et al. (2020) · World Allergy Organization Journal · doi:10.1016/j.waojou.2020.100103 · Cited by 29
A meta-analysis of anti-interleukin-13 monoclonal antibodies for uncontrolled asthma
Li, H., Wang, K., Huang, H.-T., Cheng, W., & Liu, X. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211790 · Cited by 29
“Some monoclonal antibodies, such as antiInterleukin (IL)-5 (benralizumab and mepolizumab) and anti-IgE (omalizumab), have showed clinical efficacy in treating severe refractory asthma by inhibiting T helper 2 (Th2) cytokinemediated inflammation response[5, 6].”
BackgroundTargeted Therapy for Chronıc Spontaneous Urtıcarıa: Ratıonale and Recent Progress
Giménez‐Arnau, A. M., & Salman, A. (2020) · Drugs · doi:10.1007/s40265-020-01387-9 · Cited by 34
Xu, J., Meng, Y., Jia, M., Jiang, J., Yang, Y. A., Ou, Y., Wu, Y., Yan, X., Huang, M., Adcock, I. M., et al. (2020) · Allergy · doi:10.1111/all.14727 · Cited by 30
Pediatric usage of Omalizumab: A promising one
Yu, L., Zhang, H., Pan, J., & Ye, L. (2021) · World Allergy Organization Journal · doi:10.1016/j.waojou.2021.100614 · Cited by 27
“However, a meta-analysis including 6 randomized controlled trials (RCT) found only 1 research showing significant FEV1 improvement compared with the control group.(23) A two-year follow-up study of 19 children found no significant improvement in FEV1 after any of the 3 period (16, 52, or 104 weeks) usage of omalizumab.”
"Real-life" Efficacy and Safety Aspects of 4-Year Omalizumab Treatment for Asthma
Al-Ahmad, M. S., Arifhodzic, N. A., Nurkić, J., Maher, A., Rodriguez-Bouza, T., Al‐Ahmed, N., Sadek, A., & Jusufović, E. (2018) · Medical Principles and Practice · doi:10.1159/000487482 · Cited by 26
Tolerability of Omalizumab in Asthma as a Major Compliance Factor: 10-Year Follow Up
Al-Ahmad, M. S., Nurkić, J., Maher, A., Arifhodzic, N. A., & Jusufović, E. (2018) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2018.394 · Cited by 25
Long-term evaluation of response to omalizumab therapy in real life by a novel multimodular approach
Singh, H., Peters, J. I., Kaur, Y., Maselli, D. J., & Diaz, J. D. (2019) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2019.07.026 · Cited by 22
Novel therapeutic targets for allergic airway disease in children
Giallongo, A., Parisi, G. F., Licari, A., Pulvirenti, G., Cuppari, C., Salpietro, C. D., Marseglia, G. L., & Leonardi, S. (2019) · Drugs in Context · doi:10.7573/dic.212590 · Cited by 24
Pediatric severe asthma: a case series report and perspectives on anti-IgE treatment
Mirra, V., Montella, S., & Santamaria, F. (2018) · BMC Pediatrics · doi:10.1186/s12887-018-1019-9 · Cited by 24
Menzella, F., Latorre, M., Ruggiero, P., Bagnasco, D., & Heffler, E. M. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1613367 · Cited by 18
“Omalizumab, a fully humanized monoclonal anti-IgE antibody (mAb), was the first available biologic agent for severe allergic asthma [13], with a demonstrated long-term efficacy and safety in”
BackgroundColombo, G. L., Matteo, S. D., Martinotti, C., Oselin, M., Valentino, M. C., Bruno, G. M., Pitotti, C., & Menzella, F. (2019) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466619841350 · Cited by 17
Can the response to Omalizumab be influenced by treatment duration? A real-life study
Sposato, B., Scalese, M., Latorre, M., Novelli, F., Scichilone, N., Milanese, M., Olivieri, C., Perrella, A., & Paggiaro, P. (2017) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2017.03.004 · Cited by 15
“We did not find any withdrawal or dosage reduction of ICS contrariwise of what observed by other authors [4,5,11,12].”
ResultA clinical follow‐up of omalizumab in routine treatment of allergic asthma monitored by CD‐sens
Johansson, S. G. O., Lilja, G., Hallberg, J., & Nopp, A. (2018) · Immunity Inflammation and Disease · doi:10.1002/iid3.225 · Cited by 17
A drug safety review of treating eosinophilic asthma with monoclonal antibodies
Mitchell, P., & Leigh, R. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1675634 · Cited by 15
“The adverse reactions most commonly observed among patients treated with omalizumab in pre-marketing clinical studies included injection site reaction (45%), acute respiratory viral infections (24%), sinusitis (16%), headache (15%), and pharyngitis (10%) [4,9,14,17].”
BackgroundLiu, L., Zhou, P., Wang, Z., Zhai, S., & Zhou, W. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.851177 · Cited by 15
Managing Urticarial Vasculitis: A Clinical Decision-Making Algorithm Based on Expert Consensus
Rothermel, N. D., Vera, C., Gonçalo, M., Fok, J. S., Herzog, L. S., Kocatürk, E., Neisinger, S., Pereira, M. P., Podder, I., Pyatilova, P., et al. (2024) · American Journal of Clinical Dermatology · doi:10.1007/s40257-024-00902-y · Cited by 17
“In studies of urticaria and asthma, omalizumab was well tolerated, even with long-term use [16, 17].”
Ke, X., Kavati, A., Wertz, D. A., Huang, Q., Wang, L., Willey, V. J., Stephenson, J. J., Ortiz, B. D., Panettieri, R. A., & Corren, J. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.05.014 · Cited by 14
Sousa, J. L. C., Taborda‐Barata, L., & Monteiro, C. S. D. J. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1686481 · Cited by 14
Monoclonal Antibodies for the Management of Severe Asthma
Rubinsztajn, R., & Chazan, R. (2016) · Advances in experimental medicine and biology · doi:10.1007/5584_2016_29 · Cited by 13
Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review
Mansilla‐Polo, M., & Morgado‐Carrasco, D. (2024) · Dermatology and Therapy · doi:10.1007/s13555-024-01166-4 · Cited by 15
The safety of monoclonal antibodies in asthma
Passalacqua, G., Matucci, A., Vultaggio, A., Bagnasco, D., Mincarini, M., Maggi, E., & Canonica, G. W. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1186641 · Cited by 11
Selection of Biologics in Severe Asthma: A Multifaceted Algorithm
Davila, I. J., Quirce, S., & Olaguibel, J. (2019) · Journal of Investigational Allergology and Clinical Immunology · doi:10.18176/jiaci.0398 · Cited by 11
Said, A. H. A., Cushen, B., & Costello, R. W. (2017) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622317690494 · Cited by 12
Hamada, S., Kuroe, A., & Tsukino, M. (2017) · Revista Portuguesa de Pneumologia · doi:10.1016/j.rppnen.2017.05.002 · Cited by 11
Anaphylaxis to Mepolizumab and Omalizumab in a Single Patient: Is Polysorbate the Culprit?
Bergmann, K., Maurer, M., Church, M. K., & Zuberbier, T. (2020) · Journal of Investigational Allergology and Clinical Immunology · doi:10.18176/jiaci.0492 · Cited by 11
Controversies and opportunities in severe asthma
Humbert, M. J. C., Busse, W. W., & Hanania, N. A. (2017) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000438 · Cited by 12
Pablo‐Torres, C., Garcia-Escribano, C., Romeo, M. A., Gómez‐Casado, C., Solera, R. A., Bueno‐Cabrera, J. L., Martos, M. D. M. R., Iglesias‐Cadarso, A., Tarín, C., Agache, I. O., et al. (2023) · Frontiers in Allergy · doi:10.3389/falgy.2023.1129248 · Cited by 11
Zeng, D., Li, W., Zhou, J., Wen, X. B., Chen, S., Xie, X., Zang, N., Deng, Y., Luo, R., Rizvi, S. A. A., et al. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-7314 · Cited by 11
“Although omalizumab is safe and effective, it is expensive, and there are no current guidelines for discontinuation (8).”
BackgroundSelf-citationComparative Study cf Biosimilar Genolar® Clinical Efficacy оп the Randomized Phase III Study Results
Nenasheva, N. M., Averyanov, A., Il'ina, N. I., Avdeev, S. N., Osipova, G. L., Rubanik, T. V., Зорин, В. Н., Molotkov, A. O., Кузубова, Н. А., Kostina, N. E., et al. (2020) · PULMONOLOGIYA · doi:10.18093/0869-0189-2020-30-6-782-796 · Cited by 10
McComish, J. S., Slade, C. A., Buizen, L., Paul, S. K., Chatelier, J., Unglik, G. A., Nicholls, K. A., Spriggs, K., Chan, S., Godsell, J. D., et al. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.04.008 · Cited by 8
Müller, M., Igarashi, A., Hashiguchi, K., Kappel, M., Paolini, F., Yoshisue, H., Funakubo, M., Sharma, H., & Okano, M. (2022) · Journal of Medical Economics · doi:10.1080/13696998.2022.2033051 · Cited by 9
Beliefs and preferences regarding biological treatments for severe asthma
Bikov, A., Oğuzülgen, İ. K., Baiardini, I., Contoli, M., Emelyanov, A. V., Fassio, O., Ivancevich, J. C., Кайдашев, І. П., Kowal, K., Labor, M., et al. (2020) · World Allergy Organization Journal · doi:10.1016/j.waojou.2020.100441 · Cited by 8
“Omalizumab, an anti-IgE antibody was introduced in the early 2000s(4) it was found to have glucocorticoid-sparing benefits and a significant reduction in asthma exacerbation rate.(5) Although the adverse event profile was comparable to placebo in the original randomized controlled trials,(4,5) a recent longterm analys…”
BackgroundLi, J., Yang, J., Kong, L., Huang, Y., Chen, P., Yan, X., Liu, X., Zho, X., Liu, J., Zhu, X., et al. (2020) · Asian Pacific Journal of Allergy and Immunology · doi:10.12932/ap-260819-0630 · Cited by 8
The role of omalizumab in the treatment of chronic rhinosinusitis with nasal polyposis
Aldinger, J. P., Dobyns, T., Lam, K. K., & Han, J. K. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1962282 · Cited by 7
“in asthma patient with very few significant events [44].”
BackgroundReal-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
Torres-Duque, C. A., Ocampo-Gómez, J., Castillo, M. M., Rosales, D. J. C., Montoya, Á. M. G., Rodríguez, F., Ortega, I. P., Durán-Silva, M., Reynales, H., García, E., et al. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-022-02246-x · Cited by 7
Effects of bronchial thermoplasty and cryoablation on airway smooth muscle
Li, X., Xie, S., Li, G., Zeng, J., Duan, H.-X., & Wang, C. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001681 · Cited by 7
“The heterogeneity of airway inflammation in patients with severe asthma has led to the recognition of multiple distinct endotypes, allowing the use of novel specific biologics such as anti-immunoglobulin E and anti-interleukin 5 monoclonal antibodies.([2-6]) Refractory asthma is not well controlled even with high dose…”
BackgroundTugay, D., Top, M., Aydın, Ö., Bavbek, S., Damadoğlu, E., Erkekol, F. Ö., Kalkan, İ. K., Kalyoncu, A. F., Karakaya, G., Oğuzülgen, İ. K., et al. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2023.2209417 · Cited by 6
Omalizumab therapy for children and adolescents with severe allergic asthma
Romano, C. P. (2015) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2015.1083860 · Cited by 8
“Recently, a systematic review and meta-analysis including six randomized controlled trials totaling 2749 patients confirmed for omalizumab an acceptable safety profile even when used for ‡52 weeks [37].”
BackgroundМесто омализумаба в терапии аллергических заболеваний
Курбачёва, О. М., & Галицкая, М. А. (2019) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2019-15-38-49
Xiao, Q., Huang, Y., Xue, B., & Wang, M. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1573596 · Cited by 5
Nurkić, J., Al-Ahmad, M. S., Maher, A., Arifhodzic, N. A., & Jusufović, E. (2018) · Medicinski Glasnik · doi:10.17392/972-19 · Cited by 5
“Based on current data it is still unclear when omalizumab treatment should be stopped (9).”
BackgroundLooking beyond the magic bullet: Novel asthma drugs or education, which works better?
Masekela, R., Levin, M. E., Jeena, P. M., Annamalai, M., Naidoo, V., Niekerk, A. V., Hawarden, D., Emanuel, S., Katz, H., Zar, H. J., et al. (2018) · South African Medical Journal · doi:10.7196/samj.2018.v108i8.13163 · Cited by 5
“[15] During a 1-year study, OM was found to be safe, it increased quality of life and global evaluation of treatment effectiveness, and allowed complete withdrawal of steroids with no increase in adverse drug reactions (evidence level A).[16,17] Evidence for the use of OM in children with severe persistent asthma is l…”
BackgroundLi, D., Wang, Z., Hou, L., Wang, N., Tian, B., Xie, X., Guo, Y., & Wang, Y. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2025.1755023 · Cited by 4
Pharmacoeconomic analysis of therapy with reslizumab in severe eosinophilic asthma
Kulikov, A. Y., Makarova, E. I., Avdeev, S. N., Айсанов, З. Р., Arkhipov, V. V., Emelyanov, A. V., Il'ina, N. I., Kurbacheva, O. M., Matveev, N. V., Nenasheva, N. M., et al. (2018) · PULMONOLOGIYA · doi:10.18093/0869-0189-2018-28-1-50-60 · Cited by 4
Omalizumab induced Takotsubo syndrome: case report
Aguiar-Ricardo, I., Nunes-Ferreira, A., Roda, Â., & Rosário, L. B. (2019) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/yty155 · Cited by 4
“These adverse effects were not confirmed in subsequent studies.(14,15) Regarding these controversies, coupled with study limitations such as baseline discrepancies in asthma severity and cardiovascular risk factors between the two groups, as well as the elevated dropout rate, further evidence is needed to definitively…”
Potential Role of Mast Cells in Regulating Corticosteroid Insensitivity in Severe Asthma
Alzahrani, A., Hussain, A., Alhadian, F., Hakeem, J., Douaoui, S., Tliba, O., Bradding, P., & Amrani, Y. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-63046-1_1 · Cited by 5
Yang, C., Cho, Y., & Chu, C. (2017) · Dermatologica Sinica · doi:10.1016/j.dsi.2017.05.003 · Cited by 3
Omalizumab improves forced expiratory volume in 1 second in patients with severe asthma
Pałgan, K., Żbikowska-Götz, M., Lis, K., Chrzaniecka, E., & Bartuzi, Z. (2018) · Advances in Dermatology and Allergology · doi:10.5114/ada.2018.77241 · Cited by 3
“[5] showed that biological therapy with omalizumab is, most of all, safe and also reduces exacerbations, improves the quality of life and increases FEV 1 in patients with severe asthma.”
BackgroundSafety and efficiency of using Omaulizumab in bronchial asthma
Strel’tsov, E. A., Demidov, V. S., Tsoy, L. V., Korovina, M. E., Razyschikova, N. M., & Karzhauova, А. E. (2019) · Medical Herald of the South of Russia · doi:10.21886/2219-8075-2019-10-2-6-12 · Cited by 3
Gene Therapy for Immunoglobulin E, Complement-Mediated, and Eosinophilic Disorders
Pagovich, O. E., & Crystal, R. G. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.039 · Cited by 2
Personalized targeted therapy of moderate and severe atopic asthma in Russia
Семеновна, К. Д., Pavlova, K. S., Kurbacheva, O. M., & Ilina, N. I. (2022) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-4-15-23 · Cited by 2
Ansarin, K., Attaran, D., Jamaati, H., Masjedi, M. R., Abtahi, H., Alavi, A., Aliyali, M., Asnaashari, A. M. H., Faridhosseini, R., Ghayumi, S. M. A., et al. (2015) · PubMed Central · Cited by 1
Obojski, A., Wełna, P., & Pawłowicz, R. (2016) · Alergologia Polska - Polish Journal of Allergology · doi:10.1016/j.alergo.2016.10.007 · Cited by 1
Development of Airway Allergic Diseases and Immunotherapy in Children
Kim, J. K., Kang, S. I., & Kim, D. W. (2019) · Korean Journal of Otorhinolaryngology - Head and Neck Surgery · doi:10.3342/kjorl-hns.2019.00143 · Cited by 1
Consenso chileno SER-SOCHINEP para el manejo del asma severo en el niño
Ana María Herrera, G., Selim Abara, E., Cecilia Álvarez, G., Claudia Astudillo, M., Corrales, R., Evelyn Chala, C., Tatiana Espinoza, P., Andrés Koppmann, A., Viviana Lezana, S., Rossana Mamani, J., et al. (2016) · Revista chilena de enfermedades respiratorias · doi:10.4067/s0717-73482016000200005 · Cited by 6
Ana María Herrera, G., Jury Hernández, C., Perillán, J., Viviana Lezana, S., Cecilia Álvarez, G., Marinovic, M. A., C, P. N., B, C. C., & Campusano, L. (2016) · Revista chilena de enfermedades respiratorias · doi:10.4067/s0717-73482016000300004 · Cited by 3
Direct cost analysis for patients with severe asthma receiving omalizumab treatment
Ateş, H., Aksu, K., Özdedeoğlu, Ö., Akdoğan, B. B., Kalkan, İ. K., Buhari, G. K., & Öner, F. (2021) · Journal of Health Sciences and Medicine · doi:10.32322/jhsm.959689 · Cited by 1
Current Management of Severe Refractory Asthma in Italy: Analysis of Real-World Data
Pedrini, A., Rossi, E., Calabria, S., Dondi, L., & Martini, N. (2017) · Global & Regional Health Technology Assessment · doi:10.33393/grhta.2017.397 · Cited by 6
Omalizumab no Tratamento do Penfigóide Bolhoso - O Estado da Arte
Mendes‐Bastos, P., Cunha, D., & Cardoso, J. (2016) · Journal of the Portuguese Society of Dermatology and Venereology · doi:10.29021/spdv.74.1.513
Modern Molecular Therapies for Application in Managing Childhood Asthma
Hoch, H. E., Anderson, W. C., & Szefler, S. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-44887-1.00048-1 · Cited by 1
Systematic Reviews on Pharmacological Treatment of Asthma and Chronic Obstructive Pulmonary Disease
Rodrigo, G. J. (2018) · Barcelona Respiratory Network · doi:10.23866/brnrev:2017-0020
Drugs That Act on the Respiratory Tract
Coupe, B., Griffiths, A. L., & Davies, G. A. (2016) · Side effects of drugs annual · doi:10.1016/bs.seda.2016.08.008
Prospective for Biologics in the Fields of Asthma and Related Allergic Disorders
Homma, T., Kuwahara, N., & Sagara, H. (2018) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.107.771
Kronik spontan ürtikerde omalizumab tedavisinin etkinliği: Retrospektif bir çalışma
Yıldırım, F. (2020) · Turkish Journal of Clinics and Laboratory · doi:10.18663/tjcl.772155
Eosinophilic asthma and the role of monoclonal antibodies
Jarrell, L. (2021) · The Nurse Practitioner · doi:10.1097/01.npr.0000737188.21326.c1
Chen, F., Zhang, J., Yang, H., & Wang, F. (2018) · Translational bioinformatics · doi:10.1007/978-981-10-8764-6_17
Zak, S. M., Benscoter, D. T., Castro, M., & Guilbert, T. W. (2020) · Respiratory medicine · doi:10.1007/978-3-030-54924-4_42
Precision Medicine in Respiratory Care: Where do We Stand Now?
Maheshwarappa, H. M., & Mishra, S. (2023) · Indian Journal of Respiratory Care · doi:10.5005/jp-journals-11010-1068
Pediatric usage of Omalizumab: a promising onePreprint
Lin, Y., Huishan, Z., Jianwei, P., & Ye, L. (2024) · doi:10.22541/au.170666410.01869851/v1
Kokhan, B., & Ocheredko, O. M. (2024) · Перспективи та інновації науки · doi:10.52058/2786-4952-2024-12(46)-1461-1473
Metadata
- Authors
- Lai, T., Wang, S., Xu, Z., Zhang, C., Zhao, Y., Hu, Y., Cao, C., Ying, S., Chen, Z., Li, W., Wu, B., & Shen, H.
- Affiliations
- Guangdong Medical College (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
- State Key Laboratory of Respiratory Disease (CN)
- Corresponding author
- Wu, Bin
- Shen, Huahao
- ORCID
- Venue
- Scientific Reports
- Published
- 2015-02-03
- Volume
- 5
- Issue
- 1
- Pages
- 8191-8191
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC4314644
- OpenAlex
- W2019947521
- Cited by
- 103
- References
- 68
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 5 · 2023: 5 · 2022: 4 · 2021: 6 · 2020: 14 · 2019: 14 · 2018: 19 · 2017: 15 · 2016: 12 · 2015: 4
- FWCI
- 2.05
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-08-14)
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eSpace (Curtin University) (submittedVersion)
- Funders
- National Natural Science Foundation of China (81370126, 2012BAI05B01)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- omalizumab, allergic asthma, long-term efficacy, drug safety, asthma exacerbations, inhaled corticosteroid withdrawal, quality of life, cost-effectiveness, anti-IgE therapy
- MeSH terms
- Omalizumab, Age Factors, Asthma, Clinical Trials as Topic, Humans, Severity of Illness Index, Databases, Factual, Treatment Outcome, Anti-Allergic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


